Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

NCT ID: NCT02118896

Last Updated: 2024-11-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

850 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-02-24

Study Completion Date

2009-10-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to offer patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) the possibility to continue FK506E (MR4) until commercial availability of the drug and to record long term efficacy and safety data.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study was to asses the safety and efficacy of FK506E (MR4) as a long-term treatment in transplant recipients. Only patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) and had received at least one dose of study medication were enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Transplantation Liver Transplantation Kidney Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1: FK506E (MR4)

Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.

Group Type EXPERIMENTAL

FK506E

Intervention Type DRUG

oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FK506E

oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Astagraf XL Advagraf Graceptor MR4 Prograf XL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who had already participated in the previous phase II pharmacokinetic or phase III studies with FK506E (MR4).
* Patients capable of understanding the purpose and risks of the study, who had been fully informed and given written informed consent to participate in the study.

Exclusion Criteria

* Pregnant women or nursing mothers.
* Women unwilling or unable to use adequate contraception during the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Astellas Pharma Europe Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Central Contact

Role: STUDY_CHAIR

Astellas Pharma Europe Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital

Cincinnati, Ohio, United States

Site Status

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Site Status

Princess Alexandra Hospital

Brisbane, Queensland, Australia

Site Status

Austin Hospital

Heidelberg, Victoria, Australia

Site Status

Royal Melbourne Hospital

Melbourne, Victoria, Australia

Site Status

Landeskrankenhaus Innsbruck

Innsbruck, , Austria

Site Status

AKN Wien

Vienna, , Austria

Site Status

Hospital Erasme

Brussels, , Belgium

Site Status

Cliniques Universitaires St. Luc

Brussels, , Belgium

Site Status

Departement Heelkunde

Ghent, , Belgium

Site Status

Universitair Ziekenhuis Gasthuisberg

Leuven, , Belgium

Site Status

Domaine Universitaire du Sart Tillman

Liège, , Belgium

Site Status

Hospital da Clínicas da UNICAMP

Campinas, , Brazil

Site Status

Hospital São Francisco

Porto Alegre, , Brazil

Site Status

Irmandade da Santa Casa de Misericordia de Porto Alegre

Porto Alegre, , Brazil

Site Status

Hospital Geral de Bonsucesso

Rio de Janeiro, , Brazil

Site Status

University of Alberta

Edmonton, Alberta, Canada

Site Status

London Health Sciences Centre

London, Ontario, Canada

Site Status

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Site Status

Institut de Cardiologie de Montréal

Montreal, Quebec, Canada

Site Status

Centre Hospitalier de l'Universite de Montreal (CHUM)

Montreal, Quebec, Canada

Site Status

Royal Victoria Hospital

Montreal, Quebec, Canada

Site Status

Vancouver Hospital & Health Sciences Centre

Vancouver, , Canada

Site Status

IKEM

Prague, , Czechia

Site Status

Skejby University Hospital

Århus N, , Denmark

Site Status

Helsinki University Central Hospital

Helsinki, , Finland

Site Status

Hôpital Bicêtre

Le Kremlin-Bicêtre, Bicetre Cedex, France

Site Status

Hopital Saint-Eloi

Montpellier, Cedex 05, France

Site Status

Hopital Laennec

Nantes, Cedex 1, France

Site Status

Hotel Dieu

Nantes, Cedex 1, France

Site Status

Service de Nephrologie

Nice, Cedex 1, France

Site Status

Hôpital Edouard Hérriot

Lyon, Cedex 3, France

Site Status

Hôpital Lapeyronie

Montpellier, Cedex 5, France

Site Status

Hôpital Rangueil

Toulouse, Cedex 9, France

Site Status

Hôpital Calmette

Lille, Cedex, France

Site Status

Hopital Pontchaillou

Rennes, Cedex, France

Site Status

Hôpital Beaujon

Clichy, , France

Site Status

Hôpital Henri Mondor

Créteil, , France

Site Status

Hôpital Henri Mondor

Créteil, , France

Site Status

Chu Nord

Grenoble, , France

Site Status

CHU Saint-Etienne

Saint-Etienne, , France

Site Status

Hôpital Hautepierre

Strasbourg, , France

Site Status

Hopital Paul Brousse

Villejuif, , France

Site Status

Herz- und Diabeteszentrum NRW

Bad Oeynhausen, , Germany

Site Status

Universitätsklinik Charité

Berlin, , Germany

Site Status

Charite Campus Virchow Klinikum

Berlin, , Germany

Site Status

Knappschaftskrankenhaus Bochum-Langendreer

Bochum, , Germany

Site Status

DR MED Wolfgang Arns

Cologne, , Germany

Site Status

Medizinische Klink IV

Erlangen, , Germany

Site Status

Universitätklinikum Essen

Essen, , Germany

Site Status

Funktionsbereich Nephrologie

Frankfurt am Main, , Germany

Site Status

Univ. Klinik und Poliklinik fuer Urologie

Halle, , Germany

Site Status

Universitäts-Krankenhaus Eppendorf

Hamburg, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Leiter Viszerale Organtransplantation

Heidelberg, , Germany

Site Status

Klinikum Rechts der Isar

München, , Germany

Site Status

Klinik und Poliklinik fuer Chirurgie

Regensburg, , Germany

Site Status

Klinikum der Universität Regensburg

Regensburg, , Germany

Site Status

Semmelweis University of Medicine

Budapest, , Hungary

Site Status

National Liver Transplantation Unit

Dublin, , Ireland

Site Status

Beaumont Private Clinic

Dublin, , Ireland

Site Status

Ospedali Riuniti di Bergamo

Bergamo, , Italy

Site Status

Unita Operativa Trapianto di Fegato e Multiorgano

Bologna, , Italy

Site Status

DISCAT - Centro Trapianti

Genova, , Italy

Site Status

Azienda Ospedaliera Ospedale Maggiore di Milano

Milan, , Italy

Site Status

Azienda Ospedaliera Policlinico di Modena

Modena, , Italy

Site Status

Azienda Ospedaliera di Padova

Padua, , Italy

Site Status

ISMETT

Palermo, , Italy

Site Status

Policlinico Universitario Agostino Gemelli

Roma, , Italy

Site Status

Unita Operativa Complessa di Chirurgia dei Trapianti

Siena, , Italy

Site Status

Clinica Chirurgica Universitaria

Udine, , Italy

Site Status

Instituto Mexicano de Transplantes Cuernava

Morelos, , Mexico

Site Status

Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"

Tlalpan, , Mexico

Site Status

Akademisch Ziekenhuis Maastricht

Maastricht, , Netherlands

Site Status

New Zealand Liver Transplant Unit

Auckland, , New Zealand

Site Status

Samodzielny Publiczny Szpital Kliniczny

Bydgoszcz, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny

Szczecin, , Poland

Site Status

Groote Schuur Hospital

Cape Town, , South Africa

Site Status

Christiaan Barnard Memorial Hospital

Cape Town, , South Africa

Site Status

St Augustine's Hospital

Durban, , South Africa

Site Status

Jacaranda Hospital

Pretoria, , South Africa

Site Status

University of Stellenbosch, Tygerberg Hospital

Tygerberg, , South Africa

Site Status

Hospital de Cruces

Barakaldo, Vizcaya, Spain

Site Status

Servicio de Nefrologia

Barcelona, , Spain

Site Status

Hospital Vall d'Hebron

Barcelona, , Spain

Site Status

Servicio de Nefrologia

Barcelona, , Spain

Site Status

Hospital Clinic i Provincial

Barcelona, , Spain

Site Status

Unidad de Trasplante Hepatico

Barcelona, , Spain

Site Status

Servicio de Nefrologia

Barcelona, , Spain

Site Status

Hospital General Universitario Gregorio Maranón

Madrid, , Spain

Site Status

Hospital Ramon y Cajal

Madrid, , Spain

Site Status

Consultas de Trasplante Renal

Madrid, , Spain

Site Status

Hospital Central de Asturias

Oviedo, , Spain

Site Status

Clinica de Navarra

Pamplona, , Spain

Site Status

Hospital Clinico Universitario de Santiago

Santiago de Compostela, , Spain

Site Status

SU/Sahlgrenska University Hospital

Gothenburg, , Sweden

Site Status

Karolinska University Hospital Huddinge

Stockholm, , Sweden

Site Status

Universitätsspital Zürich

Zurich, , Switzerland

Site Status

Walsgrove Hospital

Coventry, , United Kingdom

Site Status

Queen Elizabeth Hospital

Edgbaston, , United Kingdom

Site Status

Western Infirmary

Glasgow, , United Kingdom

Site Status

Kings College Hospital

London, , United Kingdom

Site Status

Department of Renal Medicine

Manchester, , United Kingdom

Site Status

Wythenshaw Hospital

Manchester, , United Kingdom

Site Status

The Freeman Hospital

Newcastle upon Tyne, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Brazil Canada Czechia Denmark Finland France Germany Hungary Ireland Italy Mexico Netherlands New Zealand Poland South Africa Spain Sweden Switzerland United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

https://astellasclinicalstudyresults.com/study.aspx?ID=304

Link to Results on the Astellas Clinical Study Results website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2005-005714-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

FG-506-14-02

Identifier Type: OTHER

Identifier Source: secondary_id

F506-CL-0857

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.